Drugs / Lutetium [177Lu] BL-ARC001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07274852 | Dec 2025 → Dec 2027 expected | breast cancer, head and neck squamous cell carcinoma, lung cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07232407 | Nov 2025 → Dec 2027 expected | cancer, digestive system neoplasm | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lutetium [177Lu] BL-ARC001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07274852 ↗ |
| Route | Intravenous | “Administration by intravenous infusion for a cycle of 6 weeks.” NCT07232407 ↗ |